Farmas USA

TEVA a ser posible … no nos alejemos de los 8,49 … quizás apoyo en esa alcista en los 8,4x … pero vuelta rapidito por encima de los 8,49

.

Posibles candidatos a short

AKCA

Q3 GAAP EPS of -$0.34 beats by $0.19.
Revenue of $20.62M (+7.2% Y/Y) misses by $1.92M.
 Press Release

.

y en KIN me voy a esperar a que avance un poquito mas la semana y vaya afianzandose la vela que corresponde a ese nivel mientras se va debilitando su MACD diario

.


Y a ver si esta vez me animo y no dejo pasar el tren … que con PETS ya lo comenté hace semana y media que andaban en 25medios y la cosa se fue del tiron casi un -15% mas abajo ...

Hoy posible Third Day Rule a aplicar en OMER y AVEO ( nanocap). Me ha salido en el proscreener de PRT. Yo pasaré, me ha cazado un buen resfriado y a lo sumo le meto short a AKCA y voy offline.

Estaba mirando TGTX a ver hasta donde la llevaban … se ha crecido mucho estos últimos días … vaya breakout de cuña ...
dejo el semanal ...

ESPR
Pérdidas mayores de las esperadas y castaña.
He entrado con venta de putt 35 en 37,58. Se ha caído un poco más. A ver. Parece querer remontar.

VCEL
RSI diario a 79 y el precio muy afuera de las Bollinger ...

Le meti short a AKCA en apertura. Se vera ...


pero asi anda el VIX …

.

Y no toco mas. 
precaucion al volante

Pérdidas de que?

 

 Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates 

 Esperion Therapeutics (ESPR) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.86 per share a year ago. These figures are adjusted for non-recurring items. 

 This quarterly report represents an earnings surprise of -25.37%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.86 per share when it actually produced a loss of $2.01, delivering a surprise of -8.06%. 

 Over the last four quarters, the company has surpassed consensus EPS estimates just once. 

 Esperion Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.98 million for the quarter ended September 2019, surpassing the Zacks Consensus Estimate by 5.48%. This compares to zero revenues a year ago. 

 The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. 

 Esperion Therapeutics shares have lost about 11.2% since the beginning of the year versus the S&P 500's gain of 22.7%. 

What's Next for Esperion Therapeutics?

 While Esperion Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 

 There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.